GeoVax Receives Notice of Allowance for HIV Vaccine Patent
05 Oktober 2023 - 3:00PM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced that
the U.S. Patent and Trademark Office has issued a Notice of
Allowance for Patent Application No. 17/409,574 titled “Multivalent
HIV Vaccine Boost Compositions and Methods of Use.” The
allowed claims generally cover a priming vaccination with a DNA
vector encoding multiple HIV antigens in virus-like particles
(VLPs), followed by a boost vaccination with GeoVax’s vector
platform for expressing HIV-1 antigens in VLPs utilizing
an MVA viral vector.
David Dodd, GeoVax President and CEO, commented, “Our
development priorities continue to be our next-generation COVID-19
vaccine, currently in Phase 2 clinical trials, and our cancer
immunotherapy program, with Gedeptin® as our lead product in a
Phase 1/2 clinical trial for advanced head and neck cancer. While
we are focusing on these two products in the near-term, our
long-term vision includes developing vaccines against other global
public health threats such as HIV. Although not currently under
active development, our HIV program forms an important part of the
dataset underpinning all of our MVA-based development programs. The
patent protection associated with the use of this vaccine is an
important part of this product platform.”
Mr. Dodd continued, “Earlier this year, data
were presented from a clinical study of a combinational HIV therapy
that included GeoVax’s HIV vaccine candidate, MVA62B. The goal of
the trial was to reduce or eliminate viral replication in the
absence of antiviral medications in HIV-positive individuals (a
“functional cure”). The data indicated very high levels of
immunogenicity of the treatment, particularly the induction of T
cell immunity, even though HIV infection compromises the immune
system. We are pleased that GeoVax’s MVA-vectored HIV vaccine was
selected to be a part of the experimental combination therapy and
contributed to the positive findings. MVA62B was also previously
tested in multiple clinical trials as a component of vaccine
regimens designed to induce immune responses that prevent HIV
infection. The team here at GeoVax is committed to help end the HIV
epidemic worldwide and recognizes that the consistent results of
MVA62B reflected in clinical trials to date may offer promise
towards achieving this goal. We remain committed to supporting
corporate and/or academic collaborations or partnering of this
potentially critically important vaccine.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing novel therapies and vaccines for
solid tumor cancers and many of the world’s most threatening
infectious diseases. The company’s lead program in oncology is a
novel oncolytic solid tumor gene-directed therapy, Gedeptin®,
presently in a multicenter Phase 1/2 clinical trial for advanced
head and neck cancers. GeoVax’s lead infectious disease candidate
is GEO-CM04S1, a next-generation COVID-19 vaccine targeting
high-risk immunocompromised patient populations. Currently in three
Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary
vaccine for immunocompromised patients such as those suffering from
hematologic cancers and other patient populations for whom the
current authorized COVID-19 vaccines are insufficient, and as a
booster vaccine in patients with chronic lymphocytic leukemia
(CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial
evaluating the vaccine as a more robust, durable COVID-19 booster
among healthy patients who previously received the mRNA vaccines.
GeoVax has a leadership team who have driven significant value
creation across multiple life science companies over the past
several decades. For more information, visit our
website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements
regarding GeoVax’s business plans. The words “believe,” “look
forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “could,” “target,” “potential,” “is likely,”
“will,” “expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is
contained in our periodic reports on Form 10-Q and Form 10-K that
we have filed and will file with the SEC. Any forward-looking
statement made by us herein speaks only as of the date on which it
is made. Factors or events that could cause our actual results to
differ may emerge from time to time, and it is not possible for us
to predict all of them. We undertake no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law.
Company
Contact:
info@geovax.com
678-384-7220
Investor Relations Contact:
paige.kelly@sternir.com
212-698-8699
Media Contact:
sr@roberts-communications.com
202-779-0929
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
Von Sep 2023 bis Sep 2024